Janssen Sciences Ireland UC

Lobbying Organisation Janssen Sciences Ireland UC

Date published 20 Sep, 2024

Relevant Matter Public policy or programme

Public Policy Area Health

Period 1 May, 2024 to 31 Aug, 2024

Specific Details Briefing for Opposition spokesperson on life sciences industry priorities.

Intended results To improve patient access to new medicines by modernising and speeding up the reimbursement process in line with IPHA proposals. To ensure a stable budget for new medicines reimbursements in the coming years. To protect existing levels of Regulatory Data Protection for innovative medicines at European level.

Name of person primarily responsible for lobbying on this activity Brita O'Reilly

Did any Designated Public Official(DPO) or former Designated Public Official(DPO) carry out lobbying activities on your behalf in relation to this return? You must include yourself, and answer Yes, if you are a current DPO or a DPO at any time in the past. (What is a Designated Public Official?) No

Did you manage or direct a grassroots campaign? No

Was this lobbying done on behalf of a client? No

Lobbying activity

The following activities occurred for this specific Subject Matter Area.

Meeting (1)

Meeting with Duncan Smith TD in Leinster House.

Email (1)

Email to Deputy Smith following meeting in Leinster House.

Submission (2-5)

Sharing of documents with Deputy Smith: IPHA Position Paper on reform of the reimbursement system: PWC report on Cell & Gene Therapies

Designated public officials lobbied

The following DPOs were lobbied during this return period on this specific Subject Matter Area. These DPOs were involved in at least one of the Lobbying Activities listed above, but not necessarily all of them. As returns are specific to a Subject Matter Area the above Lobbying Activities may be associated with multiple returns.

Duncan Smith TD (Dáil Éireann, the Oireachtas)